Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry

Robert C G Martin, Elizabeth Bruenderman, Allen Cohn, Bilal Piperdi, Rebecca Miksad, Jean Francois Geschwind, Alec Goldenberg, Arun Sanyal, Ellen Zigmont, Svetlana Babajanyan, Pamela Foreman, Parvez Mantry, Brendan McGuire, Pierre Gholam

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Treatment of unresectable recurrent hepatocellular carcinoma (HCC) in patients who recur after resection or orthotopic liver transplantation (OLT) remains a clinical challenge. One option is sorafenib, although little is known about its safety and tolerance in this unique patient population; therefore, we analyzed patients who underwent prior surgical resection and/or OLT and were treated with sorafenib in US cohort of GIDEON registry. In US, 645 patients were enrolled; 553 for intent to treat and 563 for safety. Data were analyzed in the safety population of 479 patients no surgery and 56 for resection or OLT. Forty-one patients underwent resection prior to the initiation of sorafenib, 15 patients had previously received an OLT, and 6 patients had both resection and OLT. Initial low starting doses (400 mg/day) were observed for more patients with prior OLT (71%) than prior resection (36%), resection and OLT (50%), concomitant OLT (25%), and no surgery (36%). Most AEs occurred in the first 4 weeks of treatment. Drug-related AEs were higher in patients with prior resection (87%), prior OLT (100%), or both (100%) than in patients with concomitant OLT (63%) or no surgery (70%). However, incidence of AEs resulting in permanent discontinuation were similar in all groups (19–38%).

Original languageEnglish (US)
Pages (from-to)688-695
Number of pages8
JournalAmerican Journal of Surgery
Volume213
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Liver Neoplasms
Registries
Liver Transplantation
Transplantation
Safety
sorafenib
Population
Hepatocellular Carcinoma

Keywords

  • Hepatocellular cancer
  • Liver
  • Recurrence
  • Resection
  • Sorafenib
  • Transplantation
  • Treatment of recurrent cancer

ASJC Scopus subject areas

  • Surgery

Cite this

Sorafenib use for recurrent hepatocellular cancer after resection or transplantation : Observations from a US regional analysis of the GIDEON registry. / Martin, Robert C G; Bruenderman, Elizabeth; Cohn, Allen; Piperdi, Bilal; Miksad, Rebecca; Geschwind, Jean Francois; Goldenberg, Alec; Sanyal, Arun; Zigmont, Ellen; Babajanyan, Svetlana; Foreman, Pamela; Mantry, Parvez; McGuire, Brendan; Gholam, Pierre.

In: American Journal of Surgery, Vol. 213, No. 4, 01.04.2017, p. 688-695.

Research output: Contribution to journalArticle

Martin, RCG, Bruenderman, E, Cohn, A, Piperdi, B, Miksad, R, Geschwind, JF, Goldenberg, A, Sanyal, A, Zigmont, E, Babajanyan, S, Foreman, P, Mantry, P, McGuire, B & Gholam, P 2017, 'Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry', American Journal of Surgery, vol. 213, no. 4, pp. 688-695. https://doi.org/10.1016/j.amjsurg.2016.10.006
Martin, Robert C G ; Bruenderman, Elizabeth ; Cohn, Allen ; Piperdi, Bilal ; Miksad, Rebecca ; Geschwind, Jean Francois ; Goldenberg, Alec ; Sanyal, Arun ; Zigmont, Ellen ; Babajanyan, Svetlana ; Foreman, Pamela ; Mantry, Parvez ; McGuire, Brendan ; Gholam, Pierre. / Sorafenib use for recurrent hepatocellular cancer after resection or transplantation : Observations from a US regional analysis of the GIDEON registry. In: American Journal of Surgery. 2017 ; Vol. 213, No. 4. pp. 688-695.
@article{0b475733380648d4abad315c5cf60573,
title = "Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry",
abstract = "Treatment of unresectable recurrent hepatocellular carcinoma (HCC) in patients who recur after resection or orthotopic liver transplantation (OLT) remains a clinical challenge. One option is sorafenib, although little is known about its safety and tolerance in this unique patient population; therefore, we analyzed patients who underwent prior surgical resection and/or OLT and were treated with sorafenib in US cohort of GIDEON registry. In US, 645 patients were enrolled; 553 for intent to treat and 563 for safety. Data were analyzed in the safety population of 479 patients no surgery and 56 for resection or OLT. Forty-one patients underwent resection prior to the initiation of sorafenib, 15 patients had previously received an OLT, and 6 patients had both resection and OLT. Initial low starting doses (400 mg/day) were observed for more patients with prior OLT (71{\%}) than prior resection (36{\%}), resection and OLT (50{\%}), concomitant OLT (25{\%}), and no surgery (36{\%}). Most AEs occurred in the first 4 weeks of treatment. Drug-related AEs were higher in patients with prior resection (87{\%}), prior OLT (100{\%}), or both (100{\%}) than in patients with concomitant OLT (63{\%}) or no surgery (70{\%}). However, incidence of AEs resulting in permanent discontinuation were similar in all groups (19–38{\%}).",
keywords = "Hepatocellular cancer, Liver, Recurrence, Resection, Sorafenib, Transplantation, Treatment of recurrent cancer",
author = "Martin, {Robert C G} and Elizabeth Bruenderman and Allen Cohn and Bilal Piperdi and Rebecca Miksad and Geschwind, {Jean Francois} and Alec Goldenberg and Arun Sanyal and Ellen Zigmont and Svetlana Babajanyan and Pamela Foreman and Parvez Mantry and Brendan McGuire and Pierre Gholam",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.amjsurg.2016.10.006",
language = "English (US)",
volume = "213",
pages = "688--695",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Sorafenib use for recurrent hepatocellular cancer after resection or transplantation

T2 - Observations from a US regional analysis of the GIDEON registry

AU - Martin, Robert C G

AU - Bruenderman, Elizabeth

AU - Cohn, Allen

AU - Piperdi, Bilal

AU - Miksad, Rebecca

AU - Geschwind, Jean Francois

AU - Goldenberg, Alec

AU - Sanyal, Arun

AU - Zigmont, Ellen

AU - Babajanyan, Svetlana

AU - Foreman, Pamela

AU - Mantry, Parvez

AU - McGuire, Brendan

AU - Gholam, Pierre

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Treatment of unresectable recurrent hepatocellular carcinoma (HCC) in patients who recur after resection or orthotopic liver transplantation (OLT) remains a clinical challenge. One option is sorafenib, although little is known about its safety and tolerance in this unique patient population; therefore, we analyzed patients who underwent prior surgical resection and/or OLT and were treated with sorafenib in US cohort of GIDEON registry. In US, 645 patients were enrolled; 553 for intent to treat and 563 for safety. Data were analyzed in the safety population of 479 patients no surgery and 56 for resection or OLT. Forty-one patients underwent resection prior to the initiation of sorafenib, 15 patients had previously received an OLT, and 6 patients had both resection and OLT. Initial low starting doses (400 mg/day) were observed for more patients with prior OLT (71%) than prior resection (36%), resection and OLT (50%), concomitant OLT (25%), and no surgery (36%). Most AEs occurred in the first 4 weeks of treatment. Drug-related AEs were higher in patients with prior resection (87%), prior OLT (100%), or both (100%) than in patients with concomitant OLT (63%) or no surgery (70%). However, incidence of AEs resulting in permanent discontinuation were similar in all groups (19–38%).

AB - Treatment of unresectable recurrent hepatocellular carcinoma (HCC) in patients who recur after resection or orthotopic liver transplantation (OLT) remains a clinical challenge. One option is sorafenib, although little is known about its safety and tolerance in this unique patient population; therefore, we analyzed patients who underwent prior surgical resection and/or OLT and were treated with sorafenib in US cohort of GIDEON registry. In US, 645 patients were enrolled; 553 for intent to treat and 563 for safety. Data were analyzed in the safety population of 479 patients no surgery and 56 for resection or OLT. Forty-one patients underwent resection prior to the initiation of sorafenib, 15 patients had previously received an OLT, and 6 patients had both resection and OLT. Initial low starting doses (400 mg/day) were observed for more patients with prior OLT (71%) than prior resection (36%), resection and OLT (50%), concomitant OLT (25%), and no surgery (36%). Most AEs occurred in the first 4 weeks of treatment. Drug-related AEs were higher in patients with prior resection (87%), prior OLT (100%), or both (100%) than in patients with concomitant OLT (63%) or no surgery (70%). However, incidence of AEs resulting in permanent discontinuation were similar in all groups (19–38%).

KW - Hepatocellular cancer

KW - Liver

KW - Recurrence

KW - Resection

KW - Sorafenib

KW - Transplantation

KW - Treatment of recurrent cancer

UR - http://www.scopus.com/inward/record.url?scp=85015357332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015357332&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2016.10.006

DO - 10.1016/j.amjsurg.2016.10.006

M3 - Article

C2 - 28318501

AN - SCOPUS:85015357332

VL - 213

SP - 688

EP - 695

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 4

ER -